Otezla Now Approved for Plaque Psoriasis Across All Severities
The approval was based on data from the phase 3 ADVANCE trial.
Plaque Psoriasis
Freedom From Disease’ in Psoriasis Is Multicomponent Concept
Definition includes five domains of management of clinical symptoms, psychosocial elements, QoL, treatment, health care team support
Biologic Therapy May Improve Renal Function in Patients With Psoriasis
Renal function in patients with psoriasis who received biologic therapy is assessed.
Guidelines for Managing Cutaneous Lupus Erythematosus
Current, evidence-based recommendations for the management of cutaneous lupus erythematosus (CLE) in the presence or absence of systemic lupus erythematosus (SLE) in adults, young people, and children are provided.
Topical Tapinarof Reduces Severity of Plaque Psoriasis
Response rate higher but more adverse events seen at week 12 in patients with plaque psoriasis receiving tapinarof versus vehicle control
Deucravacitinib Under Review for Moderate to Severe Plaque Psoriasis
The application is supported by data from the pivotal phase 3 POETYK PSO-1 and POETYK PSO-2, which included patients with moderate to severe plaque psoriasis.
Psoriasis Linked to Greater Volume of Epicardial Adipose Tissue in Men
Researchers sought to determine if severe psoriasis is associated with greater epicardial adipose tissue volumes (EAT-V).
PRP an Option for Atopic Dermatitis, Psoriasis
The clinical effects of platelet-rich plasma (PRP) on patients with atopic dermatitis and psoriasis are evaluated.
Risankizumab Is Safe as Short-term, Long-Term Treatment for Patients With Psoriasis
Safety data from risankizumab in phase 1, 2, and 3 trials involving patients with psoriasis is evaluated.
First Interchangeable Biosimilar to Humira Gets FDA Approval
The interchangeable biosimilar product may be substituted for the reference product by a pharmacist.
- Loading...
Loading...
Next post in Psoriasis
Loading... 
Loading...